Outer Thigh Study With Varied Treatment Parameters

Body Fat Disorder Clinical Trial

Official title:

Non-Invasive Fat Layer Reduction in the Lateral Thighs With a Cryolipolysis System Using Varied Treatment Parameters

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02081209
• Other study ID #: ZA14-001
• Status: Completed
• Phase: N/A
• First received: March 4, 2014
• Last updated: June 20, 2017
• Start date: February 2014
• Est. completion date: June 2017

Study information

• Verified date: June 2017
• Source: Zeltiq Aesthetics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the performance of a cryolipolysis system using various treatment parameters for non-invasive reduction of subcutaneous fat in the lateral thighs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: June 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria

1. Male or female subjects > 18 years of age and < 65 years of age.

2. Subject has clearly visible fat on the intended treatment area (lateral thighs), which in the investigator's opinion, may benefit from the treatment.

3. Subject has not had weight change exceeding 10 pounds in the preceding month.

4. Subject with body mass index (BMI) up to 30. BMI is defined as weight in pounds multiplied by 703 divided by the square of the height in inches.

5. Subject agrees to maintain his/her weight (i.e., within 5 pounds) by not making any major changes in their diet or lifestyle during the course of the study.

6. Subject has read and signed a written informed consent form.

Exclusion Criteria

1. Subject has had a surgical procedure(s) in the area of intended treatment.

2. Subject has had an invasive fat reduction procedure (e.g., liposuction, mesotherapy) in the area of intended treatment.

3. Subject has had a non-invasive fat reduction and/or body contouring procedure in the area of intended treatment within the past 2 months.

4. Subject has significant asymmetry between the lateral thighs.

5. Subject needs to administer, or has a known history of subcutaneous injections into the area of intended treatment (e.g., heparin, insulin) within the past month.

6. Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria.

7. Subject has a known history of Raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin.

8. Subject has a history of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising.

9. Subject is taking or has taken diet pills or supplements within the past month.

10. Subject has any dermatological conditions, such as moderate to excessive skin laxity, or scars in the location of the treatment sites that may interfere with the treatment or evaluation (stretch marks is not an exclusion).

11. Subject has an active implanted device such as a pacemaker, defibrillator, or drug delivery system

12. Subject is pregnant or intending to become pregnant during the study period (in the next 5 months).

13. Subject is lactating or has been lactating in the past 6 months.

14. Subject is unable or unwilling to comply with the study requirements.

15. Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.

16. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Related Conditions & MeSH terms

• Body Fat Disorder
• Lipid Metabolism Disorders

Intervention

Device:
• The Zeltiq System
Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.

Locations

Country	Name	City	State
United States	Marina Plastic Surgery	Marina del Rey	California
United States	Innovation Research Center	Pleasanton	California

Sponsors (1)

Lead Sponsor	Collaborator
Zeltiq Aesthetics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate safety and efficacy of treatment	Safety endpoint is the rate of unanticipated adverse device effects (UADE) at 8-week and 16 week post treatment. It is expected there will be zero UADE. Efficacy will be evaluated by a photo review of pre-treatment vs. 16-week post-treatment images.	16-weeks post treatment
Secondary	Reduction measured by ultrasound	Reduction in fat layer thickness, as measured by ultrasound, at 16 weeks post-treatment.	16-weeks post treatment
Secondary	Subject satisfaction	Subject satisfaction as assessed by questionnaires.	16-weeks post treatment